NANOBIOTIX Announces Presentation Of First Data From Phase 1 Study Evaluating NBTXR3 For Patients With Locally Advanced Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix (NASDAQ:NBTX) has announced new clinical data from a Phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with pancreatic ductal adenocarcinoma (PDAC). The study showed a tumor disease control rate of 92.3% in 13 patients evaluable for efficacy, and a median overall survival of 21 months from diagnosis. The data suggest treatment feasibility and promising, durable anti-tumor efficacy of radiotherapy-activated NBTXR3 in this population and support rationale for later stage development in pancreatic cancer.
September 28, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nanobiotix's Phase 1 study results show promising efficacy of NBTXR3 in treating pancreatic cancer, which could potentially lead to later stage development and commercialization of the product.
The positive results from the Phase 1 study of NBTXR3 indicate a high potential for the product's efficacy in treating pancreatic cancer. This could lead to further development and eventual commercialization of the product, which would likely have a positive impact on Nanobiotix's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100